CGEN
Compugen Ltd. NASDAQ Listed Aug 11, 2000$2.40
+2.78%
vs $2.34
Mkt Cap $227.4M
52w Low $1.30
57.0% of range
52w High $3.24
50d MA $2.24
200d MA $2.09
P/E (TTM)
6.3x
EV/EBITDA
2.1x
P/B
2.2x
Debt/Equity
0.0x
ROE
34.4%
P/FCF
7.2x
RSI (14)
41.60
ATR (14)
$0.11
Beta
2.77
50d MA
$2.24
200d MA
$2.09
Avg Volume
260.8K
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Azrieli Center · Holon, L3 5885849 · IL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | BMO | -0.08 | -0.07 | +12.5% | 2.35 | -0.4% | +1.3% | +0.0% | -4.2% | +0.9% | +4.8% | — |
| May 18, 2026 | BMO | -0.07 | -0.08 | -14.3% | 2.75 | +3.3% | +4.0% | -4.5% | -0.7% | -3.7% | +7.3% | — |
| Mar 2, 2026 | BMO | -0.07 | 0.60 | +957.1% | 2.25 | -0.9% | -11.1% | +7.0% | -4.2% | +1.5% | +3.4% | — |
| Nov 10, 2025 | BMO | -0.09 | -0.07 | +22.2% | 1.67 | +0.0% | +3.0% | -2.3% | -1.8% | -0.6% | -3.0% | — |
| Aug 6, 2025 | BMO | -0.07 | -0.08 | -14.3% | 1.46 | +2.1% | -1.4% | +4.2% | +0.0% | -2.0% | +0.7% | — |
| May 19, 2025 | BMO | -0.06 | -0.08 | -33.3% | 1.39 | +0.0% | +1.4% | -1.4% | +5.8% | -1.4% | -1.4% | — |
| Mar 4, 2025 | BMO | 0.07 | -0.07 | -200.0% | 1.68 | +2.4% | +7.7% | -7.7% | -0.6% | -4.2% | +1.9% | — |
| Nov 12, 2024 | BMO | 0.06 | 0.01 | -83.3% | 1.60 | +2.5% | -0.6% | -6.3% | -5.4% | +1.4% | +0.7% | — |
| Aug 6, 2024 | BMO | -0.08 | -0.02 | +75.0% | 1.72 | +1.2% | -5.2% | +7.4% | +0.0% | -4.6% | +4.8% | — |
| May 20, 2024 | BMO | -0.10 | -0.08 | +20.0% | 1.74 | +7.5% | +6.9% | +25.8% | -3.0% | +7.5% | +3.3% | — |
| Mar 5, 2024 | BMO | 0.10 | 0.11 | +10.0% | 2.55 | +3.9% | +0.4% | +3.5% | +10.9% | -5.4% | +0.7% | — |
| Nov 7, 2023 | BMO | -0.09 | -0.11 | -22.2% | 0.68 | +4.1% | -5.9% | -7.2% | -3.0% | -8.1% | +9.6% | — |
| Aug 7, 2023 | BMO | -0.13 | -0.11 | +15.4% | 1.03 | +0.0% | +1.9% | +0.0% | +1.9% | +3.7% | +0.0% | — |
| May 15, 2023 | AMC | -0.12 | -0.11 | +8.3% | 0.81 | -2.1% | -5.5% | -0.1% | -1.2% | +0.0% | +5.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 21 | Truist | Maintains | Buy → Buy | — | $1.74 | $1.87 | +7.5% | +6.9% | +25.8% | -3.0% | +7.5% | +3.3% |
| Mar 8 | Truist | Maintains | Buy → Buy | — | $2.65 | $2.72 | +2.6% | +10.9% | -5.4% | +0.7% | +0.4% | -4.6% |
| Dec 19 | Stifel | Maintains | Buy → Buy | — | $0.73 | $2.03 | +178.1% | +174.0% | -7.5% | -5.9% | -3.4% | +2.4% |
| Aug 23 | Truist | Maintains | Buy → Buy | — | $1.02 | $1.13 | +10.8% | +19.6% | -3.3% | -2.5% | +0.9% | -1.7% |
| Aug 7 | EF Hutton | Maintains | Buy → Buy | — | $1.12 | $1.12 | +0.0% | -8.0% | +1.9% | +0.0% | +1.9% | +3.7% |
| Jun 6 | EF Hutton | Maintains | Buy → Buy | — | $1.12 | $1.15 | +2.7% | +13.4% | -4.7% | +5.0% | +3.1% | +5.3% |
| May 26 | EF Hutton | Maintains | Buy → Buy | — | $0.96 | $1.00 | +4.1% | +10.7% | +0.0% | -3.8% | +1.0% | +1.9% |
| May 24 | EF Hutton | Maintains | Buy → Buy | — | $0.82 | $0.84 | +2.2% | +13.3% | +3.0% | +10.7% | +0.0% | -3.8% |
| May 16 | Oppenheimer | Maintains | Outperform → Outperform | — | $0.81 | $0.80 | -2.1% | -5.5% | -0.1% | -1.2% | +0.0% | +5.3% |
| Feb 28 | Oppenheimer | Maintains | Outperform → Outperform | — | $0.76 | $0.77 | +1.1% | +3.8% | +3.0% | -2.1% | +5.6% | +3.6% |
| Feb 8 | Jefferies | Downgrade | Hold → Underperform | — | $0.94 | $0.94 | -0.0% | -10.3% | -6.3% | +3.3% | -4.4% | +6.3% |
| Jan 5 | EF Hutton | Maintains | Buy → Buy | — | $0.76 | $0.82 | +7.8% | +15.7% | -1.4% | +3.7% | +0.0% | +9.4% |
| Nov 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $0.83 | $0.84 | +0.6% | +3.8% | +2.8% | +17.9% | -2.9% | -12.4% |
| Aug 23 | Truist | Maintains | Buy → Buy | — | $1.27 | $1.25 | -1.6% | +0.0% | +1.6% | -0.8% | -3.9% | -1.6% |
| Aug 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $1.46 | $1.51 | +3.4% | +1.4% | -2.7% | +2.8% | -1.4% | +2.7% |
| Aug 8 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $1.46 | $1.51 | +3.4% | +1.4% | -2.7% | +2.8% | -1.4% | +2.7% |
| Aug 5 | Jefferies | Downgrade | Buy → Hold | — | $1.55 | $1.50 | -3.2% | -5.8% | +1.4% | -2.7% | +2.8% | -1.4% |
| Feb 25 | SVB Leerink | Maintains | Outperform → Outperform | — | $2.93 | $2.97 | +1.4% | +3.1% | +2.3% | +2.6% | +1.9% | -7.1% |
| Feb 25 | Oppenheimer | Maintains | Outperform → Outperform | — | $2.93 | $2.97 | +1.4% | +3.1% | +2.3% | +2.6% | +1.9% | -7.1% |
| Apr 6 | SVB Leerink | Maintains | Outperform → Outperform | — | $9.16 | $9.01 | -1.6% | -4.5% | -4.9% | +1.2% | +0.0% | -2.5% |
| Aug 19 | SVB Leerink | Maintains | Outperform → Outperform | — | $17.81 | $17.89 | +0.4% | +6.4% | -2.1% | +2.0% | -1.8% | +4.6% |
| May 13 | Stifel | Maintains | Buy → Buy | — | $14.82 | $15.29 | +3.2% | -5.9% | -17.0% | +6.2% | +8.2% | -2.3% |
| May 7 | SVB Leerink | Maintains | Outperform → Outperform | — | $13.22 | $13.48 | +2.0% | +8.4% | +7.5% | +1.1% | -4.9% | -5.9% |
| Apr 22 | Roth Capital | Maintains | Buy → Buy | — | $13.96 | $14.95 | +7.1% | +5.4% | -4.1% | +5.2% | -2.2% | -4.8% |
| Mar 24 | SunTrust Robinson Humphrey | Maintains | Buy → Buy | — | $6.25 | $6.86 | +9.8% | +14.2% | +4.8% | -4.1% | +0.1% | +5.6% |
| Feb 21 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $10.51 | $10.00 | -4.9% | -4.9% | -8.8% | -0.9% | -6.6% | +7.4% |
| Jan 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.79 | $6.04 | +4.3% | +5.0% | +0.7% | +4.1% | -2.7% | +5.0% |
| Mar 29 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.00 | $4.10 | +2.5% | +11.2% | -4.5% | +0.0% | +10.6% | -4.3% |
| Mar 9 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $5.50 | $5.56 | +1.1% | -0.9% | -2.2% | +4.9% | -1.1% | -3.4% |
| Oct 15 | TD Cowen | Maintains | Outperform → Outperform | — | $5.59 | $5.83 | +4.3% | +12.3% | -2.4% | +8.5% | -3.9% | -4.2% |
| Oct 15 | FBR Capital | Maintains | Outperform → Outperform | — | $5.59 | $5.83 | +4.3% | +12.3% | -2.4% | +8.5% | -3.9% | -4.2% |
| Apr 21 | Oppenheimer | Maintains | Outperform → Outperform | — | $7.23 | $7.35 | +1.7% | -1.9% | +0.1% | -0.1% | -1.3% | -4.4% |
| Jun 18 | JMP Securities | Maintains | Market Outperform → Outperform | — | $9.06 | $9.17 | +1.2% | +5.1% | -5.7% | +0.0% | +1.1% | +0.7% |
| Mar 19 | Jefferies | Maintains | Buy → Buy | — | $11.45 | $11.89 | +3.8% | +3.9% | -3.2% | -3.4% | -5.6% | -3.2% |
| Feb 6 | McNicoll Lewis Vlak | Maintains | Buy → Buy | — | $10.71 | $10.77 | +0.6% | +0.7% | +6.4% | +10.0% | -14.5% | +1.9% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jul 9, 2026 | Levine ZuritOff | SVP, Business Development | Sell | 1,875 | $2.50 | $5K | 29,375 | +0.00% | -1.27% |
| Apr 24, 2026 | Levine ZuritOff | SVP, Business Development | Sell | 2,000 | $3.20 | $6K | 29,375 | -6.51% | -2.58% |
| Apr 24, 2026 | Ophir EranDir/Off | President and CEO | Sell | 5,000 | $3.20 | $16K | 11,375 | -6.51% | -2.58% |
No recent filings available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Silverarc Capital Management, Llc | 3,479,805 | $5M | Added | Dec 2025 |
| 2 | Renaissance Technologies Llc | 1,632,988 | $3M | Added | Mar 2026 |
| 3 | Morgan Stanley | 2,019,402 | $3M | Reduced | Dec 2025 |
| 4 | Ark Investment Management Llc | 1,049,873 | $2M | New | Mar 2026 |
| 5 | Taylor Frigon Capital Management Llc | 848,043 | $2M | Reduced | Mar 2026 |
| 6 | Northern Trust Corp | 650,868 | $1M | Reduced | Mar 2026 |
| 7 | Two Sigma Investments, Lp | 521,587 | $1M | Added | Mar 2026 |
| 8 | Ubs Group Ag | 306,708 | $653K | Reduced | Mar 2026 |
| 9 | Wells Fargo & Company/mn | 3,100 | $646K | New | Mar 2026 |
| 10 | Marshall Wace, Llp | 244,480 | $521K | Added | Mar 2026 |
| 11 | Millennium Management | 168,927 | $360K | New | Mar 2026 |
| 12 | Winton Group Ltd | 156,496 | $333K | Added | Mar 2026 |
| 13 | Citadel Advisors Llc | 112,393 | $239K | Reduced | Mar 2026 |
| 14 | Raymond James Financial Inc | 104,889 | $223K | Added | Mar 2026 |
| 15 | Stonepine Capital Management, Llc | 104,300 | $222K | Reduced | Mar 2026 |
| 16 | Kingsview Wealth Management, Llc | 83,179 | $177K | — | Mar 2026 |
| 17 | Matrix Asset Advisors Inc/ny | 93,833 | $144K | — | Dec 2025 |
| 18 | Jane Street Group, Llc | 74,300 | $114K | Reduced | Dec 2025 |
| 19 | Atom Investors Lp | 45,371 | $97K | Reduced | Mar 2026 |
| 20 | Ieq Capital, Llc | 40,000 | $85K | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 2
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | ARK Israel Innovative Technology ETF | 1,049,873 | $2M | Jan 2026 |
| 2 | Taylor Frigon Core Growth Fund | 242,969 | $639K | May 2026 |
Valuation
Market Cap
$227.4M
Enterprise Value
$73.9M
P/E (TTM)
6.29x
Forward P/E
—
PEG Ratio
-0.01x
P/B
2.19x
P/S
3.05x
P/FCF
7.20x
EV/EBITDA
2.10x
Shares Out
93.8M
Financials (TTM)
Revenue
$74.0M
Net Income
$35.2M
EBITDA
$35.2M
Free Cash Flow
$31.3M
Op Cash Flow
$31.6M
EPS Basic
$0.38
EPS Diluted
$0.38
EPS Forward
$-0.22
Gross Margin
86.9%
Op Margin
40.9%
Net Margin
47.5%
Balance Sheet
Total Assets
$156.9M
Total Liab.
$54.1M
Total Equity
$102.7M
Cash
$145.6M
LT Debt
$0
Book Value/Sh
$1.10
Debt/Equity
0.03x
Current Ratio
6.56
Quick Ratio
6.56
Returns & Growth
ROE
34.4%
ROA
22.6%
ROIC
23.2%
Rev Growth YoY
+161.1%
EPS Growth YoY
+337.5%
Price Returns
2W
-1.7%
1M
-2.1%
3M
-18.5%
6M
+36.8%
12M
+56.0%
Technicals
52W High
$3.24
52W Low
$1.30
50d MA
$2.24
200d MA
$2.09
RSI (14)
41.60
ATR (14)
$0.11
Beta
2.77
Avg Volume
261K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$4.00
High
$4.00
Low
$4.00
Median
$4.00
Data updated apr 25, 2026 12:59am
· Source: financialmodelingprep.com